These team-funded programs mobilize communities for research impact — supporting co-development of research questions and disseminating research evidence to audiences who can directly use it. This important knowledge translation work… Read More
Extends patent protection for Microbion’s proprietary inhaled pravibismane for the treatment of pulmonary infections to 2039 BOZEMAN, MT and VANCOUVER, BC — Microbion Corporation today announced that the US Patent… Read More
Survey examined healthcare professional (HCP) approaches to preventing organ damage – which impacts many people living with lupus within five years of diagnosis HCPs reported a need for earlier intervention… Read More
VANCOUVER, BC — Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its… Read More
The Phase 4 EARNEST study met its primary efficacy endpoint of remission of chronic or recurrent pouchitis at Week 14, with 31% of participants receiving vedolizumab achieving remission versus 10%… Read More
